Virax Holdings has agreed to acquire Pathway Oncology in a reverse takeover which will see the Australia-listed company gain control of a global licence for emerging anti-cancer technology.
17/03/2014 - 15:51
Virax takeover clinches anti-cancer drug
17/03/2014 - 15:51
Related Data & Insights
-
Prescient TherapeuticsClosing price for the last 90 trading daysPowered by Morningstar ®
-
Rank Company Revenue 926th Prescient Therapeutics $2.4m 1098th Kalina Power $159k 1099th A1 Investments & Resources $155k 1103rd Aus Tin Mining $152k 1104th Mithril Resources $145k 1330 listed non wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
04 Aug 2022
Radiopharm inks two new deals for cancer fight
07 Jun 2022
Board Moves June 7, 2022
25 May 2022
Chimeric closes in on cancer fighting technology
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX